CHA News

FDA Authorizes Pfizer COVID-19 Vaccine Boosters for Certain Individuals

For CEOs, CMOs, CNOs, COOs, and infection prevention, quality & patient safety, employee safety staff

This post has been archived and contains information that may be out of date.

The Food and Drug Administration (FDA) has amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to allow for a booster dose for certain individuals, including health care workers.

Specifically, the EUA allows for use of a single booster dose, to be administered at least six months after completion of the primary series, for individuals: 

  • Ages 65 and older 
  • Ages 18-64 who are at high risk of severe COVID-19  
  • Ages 18-64 whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19, including severe COVID-19 

Notably, the amended EUA authorizes boosters only for the Pfizer vaccine and for a more limited group of individuals than previously called for by the Centers for Disease Control and Prevention.